ERA therapy is known to acutely increase ET-1 levels in patients with PAH [23], reflecting an incompletely characterized neuro-hormonal or other feedback regulation loop, although the elevations in ET-1 levels may fade with chronic ERA therapy [21]. The gene discussed is EDN1; the disease is pulmonary arterial hypertension.